The sensor is "10 million times more effective" than traditional tests on patient blood samples, researchers said.
It has antibodies that can capture cancerous cells when they come into contact with an affected blood sample, and as a result weigh more.
The process causes the cancerous cells to change colour, indicating the presence of a malignant tumour, Priscila Kosaka from the Microelectronic Institute of Madrid (Spain) said.
The sensor, not expected to be on the market for another 10 years, may miss only 2 out of 10,000 samples, and can also be used to detect the onset of hepatitis and Alzheimer's, state run 'Xinhua' news agency reported.
Improvements are needed so that the nanosensor can identify the type of cancerous cells present in a sample, such as gastrointestinal or pancreatic.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
